


HEALTHCARE

## **The Vaccines Market Outlook**

Market analysis of future growth and future players by sector

 [Table of Contents](#)

## **Gayle Hamilton**

Gayle Hamilton is an analyst within the healthcare function of Business Insights. Gayle also has extensive R&D experience in the pharmaceutical and biotech industries, holding positions at Celltech (now part of UCB), Genzyme Corporation in the US, and Procter & Gamble. Previous to this Gayle graduated with a Masters degree in Biochemical Engineering from University College London.

Copyright © 2005 Business Insights Ltd

This Management Report is published by Business Insights Ltd. All rights reserved. Reproduction or redistribution of this Management Report in any form for any purpose is expressly prohibited without the prior consent of Business Insights Ltd.

The views expressed in this Management Report are those of the publisher, not of Business Insights. Business Insights Ltd accepts no liability for the accuracy or completeness of the information, advice or comment contained in this Management Report nor for any actions taken in reliance thereon.

While information, advice or comment is believed to be correct at the time of publication, no responsibility can be accepted by Business Insights Ltd for its completeness or accuracy.

# Table of Contents

## **The Vaccines Market Outlook: Growth opportunities, market analysis and forecasts**

<b>Executive summary</b>	<b>10</b>	
Introduction to vaccines & vaccine-preventable diseases	10	
Vaccines market analysis	11	
Pediatric vaccines	12	
Adult vaccines	13	
Key players in the vaccines market	14	
<b>Sources and limitations of vaccine sales data</b>	<b>16</b>	
<b>Chapter 1</b>	<b>Introduction to vaccines &amp; vaccine-preventable diseases</b>	<b>20</b>
Summary		20
Introduction		21
History of vaccines		21
Vaccines and the immune system		22
The immune system		22
Immunity by vaccination		23
Types of vaccines		23
Problems with vaccine development		24
DNA vaccines		25
Vaccine-preventable diseases		26
Measles		26
Mumps		27
Rubella		27
Diphtheria		28
Tetanus		28

Pertussis	29
Meningitis (pneumococcus, meningococcus and Hib)	29
Varicella	30
Hepatitis B	31
Influenza	31
Typhoid	32
Rabies	33

## **Chapter 2                    Vaccines market analysis                    36**

<b>Summary</b>	<b>36</b>
<b>Introduction</b>	<b>37</b>
<b>Vaccines as part of the infectious diseases market</b>	<b>37</b>
<b>Vaccine market segments</b>	<b>38</b>
<b>Leading vaccine brands</b>	<b>40</b>
<b>Key players in the vaccines market</b>	<b>41</b>
<b>Future growth drivers</b>	<b>42</b>

## **Chapter 3                    Pediatric vaccines                    44**

<b>Summary</b>	<b>44</b>
<b>Introduction</b>	<b>45</b>
<b>Pediatric immunization schedule</b>	<b>45</b>
Government recommendations	48
Immunization funding	49
US	49
Europe	50
<b>Measles/Mumps/Rubella (MMR) vaccines</b>	<b>50</b>
Brand market share and sales	51
Brand analysis	52
MMR II	52
Priorix	54
<b>Diphtheria/Tetanus/Pertussis (DTP) vaccines</b>	<b>55</b>
Brand market share and sales	56
Brand analysis	57
Infanrix & Infanrix HeXa	57
Pedarix	58
Hexavac & Pentacel	60
<b>Pneumococcal vaccines</b>	<b>61</b>
Brand market share and sales	62
Brand analysis	63
Prevnar	63

	Pneumovax 23	64
	<b>Meningococcal vaccines</b>	<b>66</b>
	Brand market share and sales	66
	<b>Other pediatric vaccines</b>	<b>68</b>
	Brand market share and sales	68
	Brand analysis	69
	Varivax	69
	Comvax	71
<b>Chapter 4</b>	<b>Adult vaccines</b>	<b>74</b>
	<b>Summary</b>	<b>74</b>
	<b>Introduction</b>	<b>75</b>
	<b>Adult vaccine population</b>	<b>75</b>
	Adolescent vaccination	75
	Elderly vaccination	76
	Traveler vaccination	78
	<b>Hepatitis vaccines</b>	<b>79</b>
	Brand market share and sales	80
	Brand analysis	81
	Engerix-B	81
	Recombivax HB	83
	Twinrix	84
	Havrix	85
	<b>Influenza vaccines</b>	<b>87</b>
	Brand market share and sales	88
	Brand analysis	89
	Fluzone	89
	Fluvirin	91
	FluMist	92
	<b>Other adult vaccines</b>	<b>94</b>
	Brand market share and sales	95
<b>Chapter 5</b>	<b>Key players in the vaccine market</b>	<b>98</b>
	<b>Summary</b>	<b>98</b>
	<b>Introduction</b>	<b>99</b>
	<b>Merck &amp; Co.</b>	<b>101</b>
	Therapeutic focus	101
	Marketed vaccines portfolio	102
	R&D pipeline	102
	ProQuad	103
	HPV (human papilloma-virus) vaccine	103

	Zoster vaccine	104
	Rotateq	104
<b>Wyeth</b>		<b>105</b>
	Therapeutic focus	105
	Marketed vaccines portfolio	106
	R&D pipeline	106
<b>GSK</b>		<b>107</b>
	Therapeutic focus	107
	Marketed vaccines portfolio	108
	R&D pipeline	109
	Boostrix	110
	Priorix-Tetra	110
	Rotarix	110
	Conjugated meningitis A/C vaccine	111
	Cervarix	111
	Streptorix	112
	Simplirix	112
<b>Sanofi-Aventis</b>		<b>113</b>
	Therapeutic focus	113
	Marketed vaccines portfolio	114
	R&D pipeline	115
	Menactra	116
	Adacel	116
<b>Chiron</b>		<b>117</b>
	Therapeutic focus	117
	Marketed vaccines portfolio	118
	R&D pipeline	119
	MeNZB	120
	ACYW meningococcal vaccine	120
<b>Index</b>		<b>121</b>

# List of Figures

Figure 1.1:	Timeline of vaccine development	21
Figure 2.2:	Comparison of US/5EU IMS sales figures and global company-reported sales figures, 2003	41
Figure 3.3:	Pediatric vaccination schedule for the US and 5 major European markets, 2004	46
Figure 3.4:	Percentage of target population vaccinated the US, 5EU and global, 2003	47
Figure 3.5:	Pediatric target population, 2005	49
Figure 3.6:	MMR II SWOT analysis	53
Figure 3.7:	Priorix SWOT analysis	55
Figure 3.8:	Infanrix & Infanrix HeXa SWOT analysis	58
Figure 3.9:	Pediarix SWOT analysis	59
Figure 3.10:	Hexavac & Pentacel SWOT analysis	60
Figure 3.11:	Prevnar SWOT analysis	64
Figure 3.12:	Pneumovax 23 SWOT analysis	65
Figure 3.13:	Varivax SWOT analysis	70
Figure 3.14:	Comvax SWOT analysis	72
Figure 4.15:	Adolescent population in the US and 5 major European markets, 2005	76
Figure 4.16:	Elderly population in the US and 5 major European markets, 2005	77
Figure 4.17:	Number of deaths from influenza and pneumonia in the US, 1995-2002	78
Figure 4.18:	Engerix-B SWOT analysis	82
Figure 4.19:	Recombivax HB SWOT analysis	83
Figure 4.20:	Twinrix SWOT analysis	85
Figure 4.21:	Havrix SWOT analysis	86
Figure 4.22:	Fluzone SWOT analysis	90
Figure 4.23:	Fluvirin SWOT analysis	92
Figure 4.24:	FluMist SWOT analysis	93
Figure 5.25:	Comparison of US/5EU IMS sales figures and global company-reported sales figures, 2003	100
Figure 5.26:	Merck & Co's global* therapeutic focus, 2003 & 2010	101
Figure 5.27:	Wyeth's global* therapeutic focus, 2003 & 2010	105
Figure 5.28:	GSK's global* therapeutic focus, 2003 & 2010	108
Figure 5.29:	Sanofi-Aventis' global* therapeutic focus, 2003 & 2010	113
Figure 5.30:	Chiron's global* therapeutic focus, 2003 & 2010	117

# List of Tables

Table 2.1:	Share of vaccines segment in anti-infectives market, US/Europe*, 2002-2003	38
Table 2.2:	Sales of vaccine products by indication and country (\$m), 2002-03	39
Table 2.3:	Top 10 vaccines in US/Europe* by sales (\$m), 2002-03	40
Table 3.4:	US/European* sales of MMR vaccines (\$m), 2002-03	52
Table 3.5:	US/European* sales of combination vaccines with a tetanus component (\$m), 2002-03	56
Table 3.6:	US/European* sales of pneumococcal vaccines (\$m), 2002-03	62
Table 3.7:	US/European* sales of meningococcal vaccines (\$m), 2002-03	67
Table 3.8:	US/European* sales of other pediatric vaccines (\$m), 2002-03	69
Table 4.9:	US/European* sales of hepatitis vaccines (\$m), 2002-03	80
Table 4.10:	US/European* sales of influenza vaccines (\$m), 2002-03	88
Table 4.11:	US/European* sales of other adult vaccines (\$m), 2002-03	95
Table 5.12:	Merck's vaccines R&D pipeline and global sales forecasts, 2007 & 2010	102
Table 5.13:	Global* sales of Wyeth's marketed vaccines portfolio (\$m), 2002-03	106
Table 5.14:	Wyeth's vaccines R&D pipeline and global sales forecasts, 2007 & 2010	107
Table 5.15:	Global* sales of GSK's marketed vaccines portfolio (\$m), 2002-03	108
Table 5.16:	GSK's vaccines R&D pipeline and global sales forecasts, 2007 & 2010	109
Table 5.17:	Global* sales of Sanofi-Aventis' marketed vaccines portfolio (\$m), 2002-03	114
Table 5.18:	Sanofi-Aventis' vaccines R&D pipeline and global sales forecasts, 2007 & 2010	115
Table 5.19:	Sales of Chiron's marketed vaccines portfolio (\$m), 2002-03	118
Table 5.20:	Chiron's vaccines R&D pipeline and global sales forecasts, 2007 & 2010	119